Impact Stories

Reviewing the impact of our work

ACE impact reports show how our guidances and work have contributed to improved patient outcomes and healthcare value in Singapore.

Latest Impact Report: COPD Inhalers

Long-acting muscarinic antagonists (LAMA) as monotherapy and in combination with long acting beta-2 agonists (LAMA+LABA) are the mainstay maintenance therapies for patients with COPD. However, due to their high cost, some patients have been using cheaper alternatives, such as a combination of inhaled corticosteroids (ICS) and LABA, which are associated with an increased risk of pneumonia. This demonstrated a high clinical need to make subsidised LAMA and LAMA+LABA available, to drive appropriate care.

Published July 2024

Read our report

Previous impact reports

NOACs

Published: December 2022

Hepatits C

Published: September 2022

The resources on this page are correct at the time of publication. Please review the associated guidances for any updates.

___________________________________________________________________________________________________________________________